State Street’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

State Street’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-119,320	Closed	-$216K	–	4670
2023 Q2	$216K	Sell	119,320 -329,912	-73%	-$603K	﹤0.01%	3986
2023 Q1	$593K	Buy	449,232 +3,513	+0.8%	+$5.74K	﹤0.01%	3687
2022 Q4	$753K	Buy	445,719 +24,361	+6%	+$30.9K	﹤0.01%	3631
2022 Q3	$780K	Buy	421,358 +85,050	+25%	+$254K	﹤0.01%	3651
2022 Q2	$1.03M	Buy	336,308 +253,888	+308%	+$1.55M	﹤0.01%	3625
2022 Q1	$595K	Buy	+82,420	New	+$811K	﹤0.01%	3974

Other funds holding PRDS

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

State Street's PRDS Position: Q3 2023 in Review

State Street sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q3 2023, closing a stake of 119,320 shares — an estimated $216K sold.

State Street first reported a position in PRDS in Q1 2022 and held it in 6 quarters. The position peaked at $1.03M in Q2 2022. 1 fund tracked by Wall St. Rank holds PRDS as of Q3 2023.

State Street reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
State Street sold 119,320 Pardes Biosciences, Inc. Common Stock shares in Q3 2023, an estimated $216K.
State Street first reported a position in Pardes Biosciences, Inc. Common Stock in Q1 2022 and held it in 6 quarters.
State Street's Pardes Biosciences, Inc. Common Stock position peaked at $1.03M in Q2 2022.
1 fund tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q3 2023.

Based on State Street's 13F filing for Q3 2023, filed 14 Nov 2023.